WillItSurvive
Pharma and healthcare groups · Japan

Kissei Pharmaceutical

kissei.co.jp ↗

Japanese specialty pharma in urology, dialysis, and women's health for 80 years.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from 2026, within 6-12 months of April 27, 2026 filing · Every call on the record Checkpoint: FDA decision on proposed TAVNEOS (avacopan) withdrawal, plus EMA CHMP review outcome
The call

Kissei survives on decades of regulatory and licensing relationships in niche drug categories, with the TAVNEOS withdrawal fight and Japan's price cuts as the near-term swing factors, not AI or bigger rivals.

Kissei is an 80-year-old Japanese drug company that makes medicines for urology, dialysis, and women's health. Its advantage comes from three things: approval from Japan's drug regulator (PMDA), coverage by Japan's government insurance (NHI), and exclusive deals to sell drugs it licensed from others. This advantage is real but fragile: it works only drug-by-drug and only lasts as long as patents and contracts hold, so bigger rivals like Merck or Japanese giants like Takeda have not bothered to compete for these small niches. The problem right now is that one key drug (avacopan, sold as TAVNEOS) faces a possible FDA withdrawal in the United States over the next 6 to 12 months, and Japan is cutting government medicine prices by 4 percent, which will shrink Kissei's sales and profits. What could change the picture is whether the FDA actually removes avacopan from the market and whether the new CEO, who took over in June 2026, can replace lost revenue with new drug deals in the pipeline.

Why
01
AI pressure: None apparent. AI tools like Iktos help Kissei design compounds faster; no AI product replaces drug trials or PMDA approval. Could AI do the core job? Unlikely.
02
Bigger players: Chugai, Astellas, Takeda, and global majors like Merck, Roche. Bigger pharma majors skip Kissei's small Japanese specialty niches because the payoff doesn't justify their scale, not because they can't enter. Could a giant copy it? Probably.
03
What protects it. 30+ years of PMDA approvals, NHI reimbursement listings, and exclusive in-licensing deals that big players find unprofitable to replicate at their scale.
What would change this call
FDA finalizes TAVNEOS withdrawal decision (proposed April 27, 2026). Loss of US approval would remove roughly 12% of FY2026 sales tied to avacopan.
EMA CHMP concludes its avacopan review opened January 30, 2026. A negative EU outcome would compound US losses and shrink TAVNEOS's addressable market.
Linzagolix or CG0070 Phase III readouts within about 6 months. Failure would signal pipeline dry spell and weaken the in-licensing growth story.
Key numbers
  • FY2026 sales rose 10.3% to ¥97.41 billion (2026-05-11)
  • TAVNEOS is about 12% of FY2026 sales, roughly ¥11.5B (2026-04-27)
  • R&D spend jumped to ¥12.889B from ¥9.474B prior year (2025-11-19)
Named risks
  • FDA proposed withdrawal of TAVNEOS US approval over alleged data-integrity issues, announced 2026-04-27. Severity: high
  • EMA CHMP review of avacopan opened 2026-01-30 could lead to EU label or market restriction. Severity: high
  • Japan's ~4% NHI drug price cut effective 2026-04-01 compresses margins sector-wide. Severity: medium
  • New CEO transition (Miyazawa, effective 2026-06-23) creates strategic uncertainty. Severity: low
  • Pipeline dependency on linzagolix and CG0070 Phase III outcomes for future growth. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Nippon Shinyakulosing toNippon Shinyaku revenue ¥170.77B vs Kissei ¥97.41B, as of 2026-07-12
KYORIN Pharmaceuticallosing toKYORIN revenue ¥126.26B exceeds Kissei's, as of 2026-07-12
Mochida Pharmaceuticallosing toMochida revenue ¥116.95B exceeds Kissei's, as of 2026-07-12
Zeria PharmaceuticalcontestingZeria revenue ¥89.16B roughly matches Kissei's ~¥97.41B, as of 2026-07-12
Chugai Pharmaceuticallosing toChugai has 7,872 employees vs Kissei's ~1,778, per 2025-06-19 profile
Questions people ask
Is Kissei Pharmaceutical profitable?
Yes. Kissei reported net income of ¥11.975 billion for the fiscal year ended March 2025, and consolidated net sales for FY ended March 2026 rose to ¥97.41 billion, up about 10.3% year on year, per its own financial filings.
Is TAVNEOS a big risk for Kissei?
Yes. TAVNEOS (avacopan) generated ¥11.524 billion in FY2026 sales, roughly 12% of revenue, but on April 27, 2026 the FDA proposed withdrawing its U.S. approval over alleged untrue statements in the original application, and EMA opened its own review on January 30, 2026.
Could AI replace Kissei Pharmaceutical?
No. Kissei's value rests on PMDA drug approvals, NHI reimbursement listings, and a 30-plus-year physician and dialysis-urology distribution network that AI cannot replicate. It already uses Iktos's Makya AI platform since July 2023 to speed compound design, but that only accelerates R&D, not commercialization.
Who is Kissei Pharmaceutical's biggest competitor?
Kissei trails larger domestic peers Nippon Shinyaku (¥170.77B revenue), KYORIN Pharmaceutical (¥126.26B), and Mochida Pharmaceutical (¥116.95B), and sits roughly on par with Zeria Pharmaceutical (¥89.16B), per StockAnalysis data as of July 2026.
Is Kissei Pharmaceutical a safe company to join?
Headcount has been stable at around 1,778 to 1,779 full-time employees as of fiscal year-end March 2026, essentially flat year over year, with no layoff signals. The company is profitable and 80 years old, though TAVNEOS regulatory risk and Japan's April 2026 NHI price cuts create near-term margin pressure.
Who owns Kissei Pharmaceutical?
Kissei is publicly traded on the Tokyo Stock Exchange Prime Market (ticker 4547) with no parent company. Institutional shareholders include Japan's Government Pension Investment Fund (about 4.4% as of March 31, 2023), Daiwa Asset Management, BlackRock Fund Advisors, and Dimensional Fund Advisors.
Timeline
  • 2026-05-11FY2026 results: consolidated net sales ¥97.41 billion, up ~10.3% year on year
  • 2026-04-27FDA's CDER proposes withdrawing U.S. approval of avacopan (TAVNEOS)
  • 2026-04-24Kissei names Keiji Miyazawa as incoming President and COO
  • 2026-04-01Japan's ~4% NHI drug price cut takes effect
  • 2026-03-31FDA warns of severe liver injury linked to avacopan
  • 2026-01-30EMA's CHMP opens review of avacopan over trial data-integrity concerns
  • 2025-10-01Fostamatinib out-licensed to Searchlight Pharma in Canada
  • 2025-07-30Viridian Therapeutics collaboration signed: $70M upfront, up to $315M milestones
  • 2025-07-01Fostamatinib commercialization launched in South Korea via JW Pharmaceutical
  • 2025-04-01Kissei opens Boston Open Innovation Office
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources